Preoperative Immunonutrition in Laparoscopic Total D2 Gastrectomy
Preoperative Immunonutrition in Laparoscopic Total D2 Gastrectomy: a Single-centre Comparative Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age >18 years
- Primary gastric cancer
- Preoperative staging I-III
- Eligible for laparoscopic D2 total gastrectomy
Exclusion Criteria:
- Acquired or congenital immunodeficiency
- Malnutrition (MNA-SF score < 12)
- Preoperative infection
- Previous gastric surgery
- ASA IV
- Emergency setting
- Para-aortic node involvement
- Intraoperative evidence of distant metastasis or peritoneal carcinosis
- Conversion to open surgery
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
patients receiving immunonutrition supply
Dietary Supplement: Immunonutrition nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
|
nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
|
|
historical control group
standard dietary advice
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
30-days postoperative complications
Time Frame: up to 30 days after discharge
|
Rate of any complication after colorectal resection
|
up to 30 days after discharge
|
|
LOS
Time Frame: up to 30 days after discharge
|
number of days between primary colorectal resection and discharge
|
up to 30 days after discharge
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pneumonia
Time Frame: up to 30 days after discharge
|
rate of radiologically demonstrated pneumonia
|
up to 30 days after discharge
|
|
Ileus
Time Frame: up to 30 days after discharge
|
rate of any ileus clinically demonstrated
|
up to 30 days after discharge
|
|
Anastomotic leak
Time Frame: up to 30 days after discharge
|
rate of any postoperative leakage of oesophagojejunal, jejunojejunal anastomosis, clinically, radiologically or endoscopically demonstrated
|
up to 30 days after discharge
|
|
Prolonged length of stay
Time Frame: up to 30 days after discharge
|
rate of any patient discharged after 15 days
|
up to 30 days after discharge
|
|
Readmission
Time Frame: up to 30 days after discharge
|
Rate of any unplanned readmission after discharge
|
up to 30 days after discharge
|
|
Mortality
Time Frame: up to 30 days after discharge
|
Rate of any mortality
|
up to 30 days after discharge
|
|
Time of first defacation
Time Frame: up to 30 days after discharge
|
time to first bowel opened to stool
|
up to 30 days after discharge
|
|
Time of tolerated fluid intake
Time Frame: up to 30 days after discharge
|
time to first tolerated fluid intake
|
up to 30 days after discharge
|
|
Time of tolerated food intake
Time Frame: up to 30 days after discharge
|
time to first tolerated food intake
|
up to 30 days after discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Protocollo xx/22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.